Actively Recruiting
Phase II Study of FOLFOX With Dabrafenib and Cetuximab or Panitumumab as First Treatment for Patients With Metastatic BRAF V600E Mutated MSS Colorectal Cancer
Led by Blokhin's Russian Cancer Research Center · Updated on 2025-05-18
64
Participants Needed
1
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate how well a combination of treatments works and how tolerable it is for people with metastatic, inoperable colorectal cancer that has a specific mutation in the BRAF gene and is microsatellite stable MSS. The study focuses on patients who have not received prior systemic treatment for this cancer type. It is a phase II clinical trial designed to assess effectiveness and side effects of the combined therapy. Participants will receive a treatment regimen called mFOLFOX6 combined with dabrafenib and either cetuximab or panitumumab. Dabrafenib is taken orally twice daily at a dose of 150 mg. Cetuximab or panitumumab is given as an intravenous infusion every two weeks, with cetuximab dosed at 500 mgm2 over 120 minutes or panitumumab at 6 mgkg over 60 minutes. The mFOLFOX6 regimen includes oxaliplatin, calcium folinate, and 5-FU administered intravenously every two weeks over specified durations and doses. Initially, participants receive 8 courses of this first-line treatment if the disease is controlled, dabrafenib and either cetuximab or panitumumab continue until the disease worsens or side effects become intolerable. During the study, participants will be monitored for up to about 3 years to see how they respond to the treatment. Assessments will include measuring tumor response rates at 8 and 16 weeks, progression-free survival for up to 24 months, time to tumor response up to 12 months, and overall survival up to 36 months. Researchers will also evaluate safety and side effects throughout the study period to understand treatment tolerability and effectiveness.
CONDITIONS
Brief Title
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Research Team
M
Mikhail Fedyanin MD
E
Evgenia Kuzmina MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here